Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMA4LNE)

Drug Name
SGN-LIV1A Drug Info
Synonyms Ladiratuzumab Vedotin
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25 Phase 2 [1]
Small-cell lung cancer 2C25.Y Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMA4LNE

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Solute carrier family 39 member 6 (SLC39A6) TTZN1CF S39A6_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Solute carrier family 39 member 6 (SLC39A6) DTT SLC39A6 6.381 6.328 7.689 6.189
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Non-small-cell lung cancer
ICD Disease Classification 2C25
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Solute carrier family 39 member 6 (SLC39A6) DTT SLC39A6 3.54E-08 0.26 0.25
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04032704) A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors. U.S. National Institutes of Health.
2 SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol Cancer Ther. 2014 Dec;13(12):2991-3000.